Trident Texofab Yönetim

Yönetim kriter kontrolleri 2/4

Trident Texofab CEO'su Hardik Desai, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı ₹ 2.20M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 21.08% ine doğrudan sahiptir ve bu hisseler ₹ 231.55M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 7.1 yıldır.

Anahtar bilgiler

Hardik Desai

İcra Kurulu Başkanı

₹2.2m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	7.4yrs
CEO sahipliği	21.1%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	7.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Hardik Desai'un ücretlendirmesi Trident Texofab'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹22m
Jun 30 2024	n/a	n/a	₹19m
Mar 31 2024	₹2m	₹2m	₹11m
Dec 31 2023	n/a	n/a	₹12m
Sep 30 2023	n/a	n/a	₹18m
Jun 30 2023	n/a	n/a	₹19m
Mar 31 2023	₹2m	₹2m	₹22m
Dec 31 2022	n/a	n/a	₹28m
Sep 30 2022	n/a	n/a	₹18m
Jun 30 2022	n/a	n/a	₹11m
Mar 31 2022	₹2m	₹2m	₹10m
Dec 31 2021	n/a	n/a	₹9m
Sep 30 2021	n/a	n/a	₹9m
Jun 30 2021	n/a	n/a	₹10m
Mar 31 2021	₹1m	₹1m	₹4m
Dec 31 2020	n/a	n/a	₹728k
Sep 30 2020	n/a	n/a	₹2m
Jun 30 2020	n/a	n/a	₹2m
Mar 31 2020	₹2m	₹2m	₹9m
Dec 31 2019	n/a	n/a	₹9m
Sep 30 2019	n/a	n/a	₹10m
Jun 30 2019	n/a	n/a	₹12m
Mar 31 2019	₹2m	₹2m	₹13m
Dec 31 2018	n/a	n/a	₹12m
Sep 30 2018	n/a	n/a	₹11m
Jun 30 2018	n/a	n/a	₹8m
Mar 31 2018	₹720k	₹720k	₹8m

Tazminat ve Piyasa: Hardik 'nin toplam tazminatı ($USD 26.08K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 42.67K ).

Tazminat ve Kazançlar: Hardik 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Hardik Desai (46 yo)

7.4yrs

Görev süresi

₹2,200,000

Tazminat

Mr. Hardik Jigishkumar Desai serves as Chairman of Trident Lifeline Pvt. Ltd., since June 27, 2022 and its Executive Director since October 01, 2020. He has been Managing Director of Trident Texofab Limite...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hardik Desai	MD & Executive Chairman	7.4yrs	₹2.20m	21.08% ₹ 231.5m
Chetan Jariwala	Whole-Time Director	no data	₹1.20m	15.48% ₹ 170.0m
Manish Halwawala	Executive & Non-Independent Director	no data	₹660.00k	0.65% ₹ 7.1m
Jenish Jariwala	Chief Financial Officer	less than a year	Veri yok	Veri yok
Rahul Jariwala	Company Secretary & Compliance officer	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

46.5yo

Ortalama Yaş

Deneyimli Yönetim: 540726 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hardik Desai	MD & Executive Chairman	16.2yrs	₹2.20m	21.08% ₹ 231.5m
Chetan Jariwala	Whole-Time Director	11.8yrs	₹1.20m	15.48% ₹ 170.0m
Manish Halwawala	Executive & Non-Independent Director	4yrs	₹660.00k	0.65% ₹ 7.1m
Natasha Francis Dsouza	Non-Executive & Independent Director	7.4yrs	₹24.00k	Veri yok
Ankita Saraiya	Non-Executive & Independent Director	6.8yrs	₹24.00k	Veri yok
Mishal Patel	Independent & Non-Executive Director	1.3yrs	Veri yok	Veri yok

7.1yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 540726 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).

Trident Texofab Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

MD & Executive Chairman recently sold ₹54m worth of stock

Trident Texofab Limited, Annual General Meeting, Sep 27, 2024

MD & Executive Chairman recently sold ₹4.5m worth of stock

Trident Texofab Limited Announces Resignation of Deepak Prakashchandra Gandhi from the Board

Trident Texofab Limited, Annual General Meeting, Sep 29, 2023

Trident Texofab Limited Announces Resignation of Vrusti Bhumik Patel as Independent Director

Recent updates

Investor sentiment improves as stock rises 40%

MD & Executive Chairman recently sold ₹54m worth of stock

Second quarter 2025 earnings released: EPS: ₹1.00 (vs ₹0.75 in 2Q 2024)

Trident Texofab Limited to Report Q2, 2025 Results on Oct 12, 2024

Trident Texofab Limited, Annual General Meeting, Sep 27, 2024

Investor sentiment improves as stock rises 15%

First quarter 2025 earnings released: EPS: ₹0.69 (vs ₹0.13 loss in 1Q 2024)

Trident Texofab Limited to Report Q1, 2025 Results on Jul 17, 2024

MD & Executive Chairman recently sold ₹4.5m worth of stock

Investor sentiment deteriorates as stock falls 16%

Third quarter 2024 earnings released: EPS: ₹0.55 (vs ₹1.14 in 3Q 2023)

Trident Texofab Limited to Report Q3, 2024 Results on Feb 14, 2024

Trident Texofab Limited to Report Q2, 2024 Results on Nov 06, 2023

Trident Texofab Limited Announces Resignation of Deepak Prakashchandra Gandhi from the Board

Investor sentiment improves as stock rises 21%

First quarter 2024 earnings released: ₹0.13 loss per share (vs ₹0.23 profit in 1Q 2023)

Trident Texofab Limited, Annual General Meeting, Sep 29, 2023

Trident Texofab Limited to Report Q1, 2024 Results on Aug 10, 2023

Trident Texofab Limited Announces Resignation of Vrusti Bhumik Patel as Independent Director

Insufficient new directors

Trident Texofab Limited Announces Resignation of Rushi Hemantkumar Jagani as Director

Trident Texofab Limited Announces Resignation of Rushi Hemantkumar Jagani as Director

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 18%

Third quarter 2023 earnings released: EPS: ₹1.14 (vs ₹0.15 in 3Q 2022)

Trident Texofab Limited to Report Q3, 2023 Results on Jan 16, 2023

Trident Texofab Limited Appoints Rahul Jariwala as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Trident Texofab Limited Approves Resignation of Sanju Patel as Company Secretary and Compliance Officer

Second quarter 2023 earnings released: EPS: ₹0.77 (vs ₹0.02 in 2Q 2022)

Trident Texofab Limited to Report Q2, 2023 Results on Oct 11, 2022

Trident Texofab Limited, Annual General Meeting, Sep 26, 2022

MD & Executive Chairman recently sold ₹3.6m worth of stock

Trident Texofab Limited Announces Resignation of Board Members

Trident Texofab Limited to Report Q1, 2023 Results on Jul 12, 2022

Trident Texofab Limited Announces Resignation of Ami Ashwinbhai Desai as Independent Director

MD & Executive Chairman recently sold ₹707k worth of stock

MD & Executive Chairman recently sold ₹5.9m worth of stock

MD & Executive Chairman recently sold ₹5.6m worth of stock

Full year 2022 earnings released: EPS: ₹0.98 (vs ₹0.35 in FY 2021)

Trident Texofab Limited to Report Q4, 2022 Results on Apr 21, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.02 (vs ₹0.14 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹0.35 (vs ₹0.90 in FY 2020)

Non-Executive Non-Independent Director has left the company

Company Secretary & Compliance Officer has left the company

Third quarter 2021 earnings released: EPS ₹0.08 (vs ₹0.24 in 3Q 2020)

Trident Texofab Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day low: ₹24.25

New 90-day high: ₹33.10

New 90-day high: ₹30.00

Second quarter 2021 earnings released: EPS ₹0.14

Trident Texofab Limited to Report Q2, 2021 Results on Nov 11, 2020

New 90-day low: ₹26.15

New 90-day low: ₹26.40

New 90-day low - ₹27.85

First quarter earnings released

Trident Texofab Limited to Report Q1, 2021 Results on Aug 20, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi